Ezh2-话题@MedSci

#Ezh2#

30篇内容 | 1945人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2250525, encodeId=9296225052533, content=<a href='/topic/show?id=5fefe188e3' target=_blank style='color:#2F92EE;'>#Ezh2#</a> <a href='/topic/show?id=793a101990ac' target=_blank style='color:#2F92EE;'>#骨髓瘤#</a>, objectTitle=Nat Commun：厦门大学刘欢/刘志强研究表明EZH2是骨髓瘤诱导的溶骨性骨破坏的可行治疗靶点, objectType=article, longId=861857, objectId=a17086185e40, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20250203/1738593385771_8538692.png, objectUrl=/article/show_article.do?id=a17086185e40, replyNumber=0, likeNumber=0, createdTime=2025-02-05, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=a17086185e40, moduleTitle=Nat Commun：厦门大学刘欢/刘志强研究表明EZH2是骨髓瘤诱导的溶骨性骨破坏的可行治疗靶点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a17086185e40)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1746924, encodeId=e5941e4692498, content=<a href='/topic/show?id=5fefe188e3' target=_blank style='color:#2F92EE;'>#Ezh2#</a>, objectTitle=全球首创EZH2抑制剂他泽司他完成中国首例患者用药, objectType=article, longId=730964, objectId=d910e309647f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d910e309647f, replyNumber=0, likeNumber=84, createdTime=2023-01-03, rootId=0, userName=fusion, userId=d2a935872940, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d910e309647f, moduleTitle=全球首创EZH2抑制剂他泽司他完成中国首例患者用药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d910e309647f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1746925, encodeId=aab91e4692586, content=<a href='/topic/show?id=5fefe188e3' target=_blank style='color:#2F92EE;'>#Ezh2#</a>, objectTitle=EZH2在滤泡淋巴瘤发生机制中的作用, objectType=article, longId=732162, objectId=a17ae32162d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a17ae32162d6, replyNumber=0, likeNumber=85, createdTime=2023-01-26, rootId=0, userName=fusion, userId=d2a935872940, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a17ae32162d6, moduleTitle=EZH2在滤泡淋巴瘤发生机制中的作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a17ae32162d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1746923, encodeId=c29b1e46923f4, content=<a href='/topic/show?id=5fefe188e3' target=_blank style='color:#2F92EE;'>#Ezh2#</a>, objectTitle=Lancet Oncol：采用EZH2抑制剂Tzemetostat治疗复发/难治性恶性胸膜间皮瘤, objectType=article, longId=727301, objectId=6669e2730156, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6669e2730156, replyNumber=0, likeNumber=84, createdTime=2022-12-22, rootId=0, userName=fusion, userId=d2a935872940, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6669e2730156, moduleTitle=Lancet Oncol：采用EZH2抑制剂Tzemetostat治疗复发/难治性恶性胸膜间皮瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6669e2730156)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1746922, encodeId=79cf1e46922d9, content=<a href='/topic/show?id=5fefe188e3' target=_blank style='color:#2F92EE;'>#Ezh2#</a>, objectTitle=Nat Commun：EZH2甲基化ERG K362位点并增强前列腺癌中TMPRSS2-ERG的致癌活性, objectType=article, longId=214243, objectId=fdf2214243e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fdf2214243e4, replyNumber=0, likeNumber=93, createdTime=2021-10-09, rootId=0, userName=fusion, userId=d2a935872940, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fdf2214243e4, moduleTitle=Nat Commun：EZH2甲基化ERG K362位点并增强前列腺癌中TMPRSS2-ERG的致癌活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fdf2214243e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1746918, encodeId=67c21e4691859, content=<a href='/topic/show?id=5fefe188e3' target=_blank style='color:#2F92EE;'>#Ezh2#</a>, objectTitle=Lancet oncol：EZH2抑制剂（EPZ-643）治疗上皮样肉瘤的疗效和安全性, objectType=article, longId=201956, objectId=2c322019565b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c322019565b, replyNumber=0, likeNumber=102, createdTime=2021-06-24, rootId=0, userName=fusion, userId=d2a935872940, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c322019565b, moduleTitle=Lancet oncol：EZH2抑制剂（EPZ-643）治疗上皮样肉瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c322019565b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1746921, encodeId=12351e4692157, content=<a href='/topic/show?id=5fefe188e3' target=_blank style='color:#2F92EE;'>#Ezh2#</a>, objectTitle=Cell Death Dis：lncRNA HOXA-AS2通过结合EZH2并抑制LATS2以促进AML发生发展, objectType=article, longId=204308, objectId=1287204308da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1287204308da, replyNumber=0, likeNumber=100, createdTime=2021-04-07, rootId=0, userName=fusion, userId=d2a935872940, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1287204308da, moduleTitle=Cell Death Dis：lncRNA HOXA-AS2通过结合EZH2并抑制LATS2以促进AML发生发展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1287204308da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1746919, encodeId=0bce1e469199a, content=<a href='/topic/show?id=5fefe188e3' target=_blank style='color:#2F92EE;'>#Ezh2#</a>, objectTitle=Lancet oncol：EZH2抑制剂，有望成为滤泡性淋巴瘤患者的新选择！, objectType=article, longId=201959, objectId=fc0c201959b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc0c201959b7, replyNumber=0, likeNumber=107, createdTime=2021-01-01, rootId=0, userName=fusion, userId=d2a935872940, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc0c201959b7, moduleTitle=Lancet oncol：EZH2抑制剂，有望成为滤泡性淋巴瘤患者的新选择！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc0c201959b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1746917, encodeId=cd2d1e469175b, content=<a href='/topic/show?id=5fefe188e3' target=_blank style='color:#2F92EE;'>#Ezh2#</a>, objectTitle=Cell Death Differ：EZH2 R342甲基化修饰促进乳腺癌的转移, objectType=article, longId=200457, objectId=5f7520045eca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f7520045eca, replyNumber=0, likeNumber=91, createdTime=2021-07-03, rootId=0, userName=fusion, userId=d2a935872940, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f7520045eca, moduleTitle=Cell Death Differ：EZH2 R342甲基化修饰促进乳腺癌的转移, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f7520045eca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1746920, encodeId=27361e46920a3, content=<a href='/topic/show?id=5fefe188e3' target=_blank style='color:#2F92EE;'>#Ezh2#</a>, objectTitle=Nat Commun：EZH2介导的PP2A失活介导乳腺癌HER2靶向治疗的耐药性, objectType=article, longId=203859, objectId=0da720385952, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0da720385952, replyNumber=0, likeNumber=102, createdTime=2021-10-17, rootId=0, userName=fusion, userId=d2a935872940, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0da720385952, moduleTitle=Nat Commun：EZH2介导的PP2A失活介导乳腺癌HER2靶向治疗的耐药性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0da720385952)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1746915, encodeId=68c71e46915e8, content=<a href='/topic/show?id=5fefe188e3' target=_blank style='color:#2F92EE;'>#Ezh2#</a>, objectTitle=Cell Death & Disease：前列腺癌中靶向Wnt/EZH2/microRNA-708信号途径能够抑制神经纤维瘤分化, objectType=article, longId=181688, objectId=e91418168864, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e91418168864, replyNumber=0, likeNumber=92, createdTime=2020-07-05, rootId=0, userName=fusion, userId=d2a935872940, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e91418168864, moduleTitle=Cell Death & Disease：前列腺癌中靶向Wnt/EZH2/microRNA-708信号途径能够抑制神经纤维瘤分化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e91418168864)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1746916, encodeId=75c41e46916da, content=<a href='/topic/show?id=5fefe188e3' target=_blank style='color:#2F92EE;'>#Ezh2#</a>, objectTitle=Oncogene：在恶性前列腺癌中HNF1B介导的SLUG抑制受EZH2抑制, objectType=article, longId=182625, objectId=c3f51826252c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c3f51826252c, replyNumber=0, likeNumber=106, createdTime=2020-08-23, rootId=0, userName=fusion, userId=d2a935872940, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c3f51826252c, moduleTitle=Oncogene：在恶性前列腺癌中HNF1B介导的SLUG抑制受EZH2抑制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c3f51826252c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1746914, encodeId=2acc1e4691468, content=<a href='/topic/show?id=5fefe188e3' target=_blank style='color:#2F92EE;'>#Ezh2#</a>, objectTitle=Blood：MELK-EZH2泛素化或可成为NKTL的治疗新靶点, objectType=article, longId=178189, objectId=69761e818964, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69761e818964, replyNumber=0, likeNumber=84, createdTime=2020-07-21, rootId=0, userName=fusion, userId=d2a935872940, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69761e818964, moduleTitle=Blood：MELK-EZH2泛素化或可成为NKTL的治疗新靶点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=69761e818964)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1746912, encodeId=1f641e46912cd, content=<a href='/topic/show?id=5fefe188e3' target=_blank style='color:#2F92EE;'>#Ezh2#</a>, objectTitle=Sci Rep：EZH2表达的增加表明膀胱上皮恶性肿瘤的可能, objectType=article, longId=156873, objectId=0a0f1568e39a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a0f1568e39a, replyNumber=0, likeNumber=77, createdTime=2019-01-31, rootId=0, userName=fusion, userId=d2a935872940, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a0f1568e39a, moduleTitle=Sci Rep：EZH2表达的增加表明膀胱上皮恶性肿瘤的可能, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a0f1568e39a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1746910, encodeId=cf6b1e46910b8, content=<a href='/topic/show?id=5fefe188e3' target=_blank style='color:#2F92EE;'>#Ezh2#</a>, objectTitle=Oncogene：在CRPC中，KDM8/JMJD5作为AR和PKM2的共激活子参与了AR/EZH2网络和肿瘤代谢, objectType=article, longId=146505, objectId=9bf214650536, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9bf214650536, replyNumber=0, likeNumber=109, createdTime=2018-08-24, rootId=0, userName=fusion, userId=d2a935872940, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9bf214650536, moduleTitle=Oncogene：在CRPC中，KDM8/JMJD5作为AR和PKM2的共激活子参与了AR/EZH2网络和肿瘤代谢, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9bf214650536)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1746913, encodeId=6d431e46913a9, content=<a href='/topic/show?id=5fefe188e3' target=_blank style='color:#2F92EE;'>#Ezh2#</a>, objectTitle=Int J Cancer：多梳家族蛋白EZH2和EED在晚期前列腺癌中能够直接调控雄激素受体, objectType=article, longId=158502, objectId=f2ca158502a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f2ca158502a0, replyNumber=0, likeNumber=92, createdTime=2019-07-02, rootId=0, userName=fusion, userId=d2a935872940, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f2ca158502a0, moduleTitle=Int J Cancer：多梳家族蛋白EZH2和EED在晚期前列腺癌中能够直接调控雄激素受体, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f2ca158502a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1746905, encodeId=1a5c1e469052c, content=<a href='/topic/show?id=5fefe188e3' target=_blank style='color:#2F92EE;'>#Ezh2#</a>, objectTitle=前景光明：BET和EZH2抑制剂治疗淋巴瘤, objectType=article, longId=131672, objectId=ff821316e2de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff821316e2de, replyNumber=0, likeNumber=101, createdTime=2018-11-06, rootId=0, userName=fusion, userId=d2a935872940, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff821316e2de, moduleTitle=前景光明：BET和EZH2抑制剂治疗淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ff821316e2de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1746911, encodeId=146e1e469119f, content=<a href='/topic/show?id=5fefe188e3' target=_blank style='color:#2F92EE;'>#Ezh2#</a>, objectTitle=Nat Commun：雄激素剥夺通过CREB-EZH2-TSP1途径促进前列腺癌的神经内分泌分化和血管生成, objectType=article, longId=150806, objectId=f841150806d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f841150806d3, replyNumber=0, likeNumber=75, createdTime=2019-05-09, rootId=0, userName=fusion, userId=d2a935872940, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f841150806d3, moduleTitle=Nat Commun：雄激素剥夺通过CREB-EZH2-TSP1途径促进前列腺癌的神经内分泌分化和血管生成, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f841150806d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1746908, encodeId=9eeb1e469089c, content=<a href='/topic/show?id=5fefe188e3' target=_blank style='color:#2F92EE;'>#Ezh2#</a>, objectTitle=Lancet oncol：Tazemetostat，EZH2抑制剂，用于B细胞非霍奇金淋巴瘤和晚期固体肿瘤治疗效率良好，且安全性良好, objectType=article, longId=134756, objectId=8eb0134e56d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8eb0134e56d7, replyNumber=0, likeNumber=139, createdTime=2018-10-08, rootId=0, userName=fusion, userId=d2a935872940, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8eb0134e56d7, moduleTitle=Lancet oncol：Tazemetostat，EZH2抑制剂，用于B细胞非霍奇金淋巴瘤和晚期固体肿瘤治疗效率良好，且安全性良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8eb0134e56d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1746907, encodeId=0a081e46907ef, content=<a href='/topic/show?id=5fefe188e3' target=_blank style='color:#2F92EE;'>#Ezh2#</a>, objectTitle=Blood：弥漫性大B细胞淋巴瘤通过激活存活信号通路或获得影响药物与靶点结合的EZH2突变，从而对EZH2抑制剂耐药, objectType=article, longId=133365, objectId=e4531333650d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4531333650d, replyNumber=0, likeNumber=113, createdTime=2018-06-16, rootId=0, userName=fusion, userId=d2a935872940, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4531333650d, moduleTitle=Blood：弥漫性大B细胞淋巴瘤通过激活存活信号通路或获得影响药物与靶点结合的EZH2突变，从而对EZH2抑制剂耐药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4531333650d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Ezh2

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#Ezh2# #骨髓瘤#

Nat Commun：厦门大学刘欢/刘志强研究表明EZH2是骨髓瘤诱导的溶骨性骨破坏的可行治疗靶点

2025-02-05发表于陕西省

fusion (审核中...)

前往app查看评论内容

#Ezh2#

全球首创EZH2抑制剂他泽司他完成中国首例患者用药

2023-01-03

fusion (审核中...)

前往app查看评论内容

#Ezh2#

EZH2在滤泡淋巴瘤发生机制中的作用

2023-01-26

fusion (审核中...)

前往app查看评论内容

#Ezh2#

Lancet Oncol：采用EZH2抑制剂Tzemetostat治疗复发/难治性恶性胸膜间皮瘤

2022-12-22

fusion (审核中...)

前往app查看评论内容

#Ezh2#

Nat Commun：EZH2甲基化ERG K362位点并增强前列腺癌中TMPRSS2-ERG的致癌活性

2021-10-09

fusion (审核中...)

前往app查看评论内容

#Ezh2#

Lancet oncol：EZH2抑制剂（EPZ-643）治疗上皮样肉瘤的疗效和安全性

2021-06-24

fusion (审核中...)

前往app查看评论内容

#Ezh2#

Cell Death Dis：lncRNA HOXA-AS2通过结合EZH2并抑制LATS2以促进AML发生发展

2021-04-07

fusion (审核中...)

前往app查看评论内容

#Ezh2#

Lancet oncol：EZH2抑制剂，有望成为滤泡性淋巴瘤患者的新选择！

2021-01-01

fusion (审核中...)

前往app查看评论内容

#Ezh2#

Cell Death Differ：EZH2 R342甲基化修饰促进乳腺癌的转移

2021-07-03

fusion (审核中...)

前往app查看评论内容

#Ezh2#

Nat Commun：EZH2介导的PP2A失活介导乳腺癌HER2靶向治疗的耐药性

2021-10-17

fusion (审核中...)

前往app查看评论内容

#Ezh2#

Cell Death & Disease：前列腺癌中靶向Wnt/EZH2/microRNA-708信号途径能够抑制神经纤维瘤分化

2020-07-05

fusion (审核中...)

前往app查看评论内容

#Ezh2#

Oncogene：在恶性前列腺癌中HNF1B介导的SLUG抑制受EZH2抑制

2020-08-23

fusion (审核中...)

前往app查看评论内容

#Ezh2#

Blood：MELK-EZH2泛素化或可成为NKTL的治疗新靶点

2020-07-21

fusion (审核中...)

前往app查看评论内容

#Ezh2#

Sci Rep：EZH2表达的增加表明膀胱上皮恶性肿瘤的可能

2019-01-31

fusion (审核中...)

前往app查看评论内容

#Ezh2#

Oncogene：在CRPC中，KDM8/JMJD5作为AR和PKM2的共激活子参与了AR/EZH2网络和肿瘤代谢

2018-08-24

fusion (审核中...)

前往app查看评论内容

#Ezh2#

Int J Cancer：多梳家族蛋白EZH2和EED在晚期前列腺癌中能够直接调控雄激素受体

2019-07-02

fusion (审核中...)

前往app查看评论内容

#Ezh2#

前景光明：BET和EZH2抑制剂治疗淋巴瘤

2018-11-06

fusion (审核中...)

前往app查看评论内容

#Ezh2#

Nat Commun：雄激素剥夺通过CREB-EZH2-TSP1途径促进前列腺癌的神经内分泌分化和血管生成

2019-05-09

fusion (审核中...)

前往app查看评论内容

#Ezh2#

Lancet oncol：Tazemetostat，EZH2抑制剂，用于B细胞非霍奇金淋巴瘤和晚期固体肿瘤治疗效率良好，且安全性良好

2018-10-08

fusion (审核中...)

前往app查看评论内容

#Ezh2#

Blood：弥漫性大B细胞淋巴瘤通过激活存活信号通路或获得影响药物与靶点结合的EZH2突变，从而对EZH2抑制剂耐药

2018-06-16

科室
- - 订阅+
  - 更多科室
工具
服务